title: [The condition--not the drug--is decisive when it comes to subsidizing. Increased objectivity in the debate on subsidized "quality of life drugs" is required].
authors.affiliation: Avdelningen för neurologi, LAH-kliniken, Motala.
authors.forename: A M
authors.initials: AM
authors.lastname: Landtblom
authors.forename: P
authors.initials: P
authors.lastname: Ertzgaard
mesh_terms: D016527:Drug Costs; D011307:Drug Prescriptions; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006292:Health Priorities; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use; D011687:Purines; D011788:Quality of Life; D000068677:Sildenafil Citrate; D013450:Sulfones; D013548:Sweden
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate